1236153-29-9

Upstream product

• 134414-14-5 11beta-(4-hydroxyphenyl)-estra-4,9-diene-3,17-dione 
• 5571-36-8 ethylene deltenone 
• 39931-88-9 (5'R,10'R,13'S)-13'-methyl-1',2',6',7',8',12',13',14',15',16'-decahydro-17'H-spiro[1,3-dioxolane-2,3'-[5,10]epoxycyclopenta[a]phenanthren]-17'-one 
• 45985-26-0 4-oxo-2,2,6,6-tetramethylpiperidin-oxyl 
• 1236153-21-1 11β-2-azidoethoxyphenyl-3-acetoxy?-e?stra-1,3,?5(10)-tri?en-17-one 
• 1236153-20-0 11β-[4-(2-azidoethoxy)phenyl]estra-4,9-diene-3,17-dione 
• 1236153-19-7 11β-[4-(2-tosyloxyethoxy)-phenyl]-estra-4,9-diene-3,17-dione 
• 875018-34-1 2,2,6,6-tetramethyl-4-(prop-2-ynylamino)-piperidone nitroxide 
• 1236153-28-8 C₄₀H₅₂N₅O₅ 

Relevant academic research and scientific papers

Synthesis of a spin-labeled anti-estrogen as a dynamic motion probe for the estrogen receptor ligand binding domain

The preparation and characterization of a novel nitroxide spin probe based on a steroidal anti-estrogen is described. The probe 5 demonstrated very high binding affinity for both the alpha and beta isoforms of the estrogen receptor-ligand binding domain. EPR spectrometric studies demonstrate conformational constraints for the ligand, consistent with the nitroxyl moiety occupying a position just beyond the receptor-solvent interface.

STEROIDAL ANTI-HORMONE HYBRIDS

Disclosed are novel compounds and compositions for inhibition of androgen and estrogen receptor signaling, methods for inhibiting androgen signaling, methods for inhibiting estrogen signaling, methods for inhibiting the interaction between a co-regulatory protein and an androgen or estrogen receptor, and methods for treating cancer.